

# H1N1 Vaccines: Market Research Report

<https://marketpublishers.com/r/H18B1E1E4D1EN.html>

Date: January 2015

Pages: 137

Price: US\$ 4,950.00 (Single User License)

ID: H18B1E1E4D1EN

## Abstracts

This report analyzes the worldwide markets for H1N1 Vaccines in US\$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -

Abbott Laboratories

CPL Biologicals Pvt. Ltd.

bioCSL

GlaxoSmithKline Plc

MedImmune, LLC

## Contents

### **I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

### **II. EXECUTIVE SUMMARY**

#### **1. GLOBAL MARKET OVERVIEW**

Resurgence of the H1N1 Virus

A Glimpse of the 2009 H1N1 Pandemic Outbreak, and the Post-Pandemic Phase

Efforts to Face Potential Pandemics

Competitive Scenario

H1N1 Influenza Vaccines and Manufacturers

#### **2. GROWTH DRIVERS/RESTRAINTS/ CHALLENGES**

Key Growth Drivers

Consumer Awareness Drives Market Growth in Developed Regions

Emerging Economies Offer Strong Potential

Threat of Antigenic Shift of H1N1 Virus Lingers

Key Growth Inhibitors

Requirement of Huge Capital and Large-Scale Investments

Stringent Regulatory Scenario

High Competition Lowers Profit Margins

Challenges Facing Healthcare Industry in Tackling Pandemics

Cumbersome Production Process, New Technologies Come to Rescue

Inefficiencies in Vaccine Distribution: A Cause of Concern

Shorter Lifecycle of Pandemic Influenza

Market Trends

Antigenic Shift of Virus Unlocks Possibilities for New Seasonal Influenza Vaccines

Quadrivalent Vaccines – A Whole New Generation of Seasonal Influenza Vaccines

Innovations in Vaccine Technology to Drive the Effort for a Universal Influenza Vaccine

Safety Concerns of Influenza Vaccines Abate

H1N1 Vaccine Sourced from Tobacco Plants

### 3. AN INSIGHT INTO THE GLOBAL VACCINES MARKET

Vaccines Market to Witness Robust Increase in Sales Driven by Robust Demand  
Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales

**Table 1.** Global Vaccines Market by Category (2014): Percentage Breakdown of Value Sales for Adult Booster, Hepatitis, HPV, Influenza, Meningococcal, Pediatric Multivalent, Pneumococcal, Rotavirus, and Shingles (includes corresponding Graph/Chart)

Competitive Scenario

**Table 2.** Global Vaccines Market by Leading Manufacturer (2014): Percentage Market Share Breakdown of Value Sales for Astra Zeneca, GlaxoSmithKline, Merck & Co, Pfizer, Sanofi Pasteur, and Others (includes corresponding Graph/Chart)

### 4. H1N1 PANDEMIC – A HISTORICAL PERSPECTIVE

Influenza A (H1N1) 2009: The Global Pandemic

**Table 3.** Global Death Toll from 2009 A H1N1 (2009-2012) (includes corresponding Graph/Chart)

**Table 4.** Mortality Rates of Major Influenza Pandemics Over the Last 100 Years (includes corresponding Graph/Chart)

Economic Impact of H1N1 Pandemic in Retrospect  
Healthcare & Pharmaceuticals  
Pork & Pork Products  
Airlines, Tourism & Hospitality  
Hand Sanitizers  
H1N1 Influenza Diagnostic Tests

**Table 5.** Global Laboratory Rapid Testing by Leading Player (2014): Percentage Market Share Breakdown of Value Sales for Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher, OraSure and Others (includes corresponding Graph/Chart)

## **5. H1N1 INFLUENZA – AN OVERVIEW**

Influenza Virus: A Quick Primer

Symptoms and Characteristics

Types of Influenza

Influenza A Virus

Influenza A (H1N1) Virus

Different Names, in Different Countries

Symptoms and Risk Factors

The Pandemic Life-Cycle

Seasonal Influenza vis-à-vis H1N1 Flu

How H1N1 Is Diagnosed?

Prevention and Vaccination Against H1N1

Prevention

Vaccination

Vaccine Virus Selection for the 2015-2016 Influenza Season

WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016

WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016

How is H1N1 Vaccine Prepared?

Egg-Based Production Process

Cell Culture-Based Technology

Recombinant Technology

Side Effects of H1N1 Vaccine

Primary Targets for Vaccination

Adverse Group for Vaccination

Treatment for Swine-Flu Infected Individuals

Anti-Virals for Pandemic (H1N1) 2009 Infection

Recommended Dosage of Anti-Virals

Rapivab (Peramivir) – The IV Flu Drug

## **6. REGULATORY APPROVALS**

FDA Approves Rapivab by BioCryst Pharmaceuticals

GSK Obtains Marketing Authorization for Quadrivalent Influenza Vaccine in the UK and Germany

Sanofi Pasteur's Review Application for Quadrivalent Influenza Vaccine Accepted by EU

MedImmune Announces FDA Approval of First Quadrivalent Flu Vaccine

Novartis Announces FDA Approval for Cell-Culture Derived Vaccine

GlaxoSmithKline Obtains FDA Approval for FLUARIXÂ QUADRIVALENT

Tianyuan Receives GMP Certification for Influenza and H1N1 Vaccine

## **7. PRODUCT LAUNCHES**

Serum Institute of India to Launch NasoVacS

Bharat Biotech to Produce Swine Flu Vaccine in Bulk

Vaxart Announces Positive Trials of its H1N1 Tablet Vaccine

A\*Star and Cytos Biotechnology Collaborate for H1N1 Vaccine

VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses

Focus Diagnostics and 3M Unveil Simplexa Test on 3M Integrated Cyclor

## **8. RECENT INDUSTRY ACTIVITY**

GSK Acquires GlycoVaxyn AG

Baxter to Divest Vero cell Vaccine Technology and Assets to Nanotherapeutics

Novartis to Divest Influenza Vaccines Business to CSL

CALIXAR and VirPath Develop Novel Manufacturing Process for Influenza Vaccines

bioCSL Restarts Manufacture of Influenza Vaccine

Novartis Begins Shipment of Seasonal Influenza Vaccines to US

bioCSL Obtains Government Contracts for Vaccine Distribution

InGen Biosciences Partners with Quidel and Diagnostic Hybrids

## **9. FOCUS ON SELECT GLOBAL PLAYERS**

Abbott Laboratories (US)

CPL Biologicals Pvt. Ltd. (India)

bioCSL (Australia)

GlaxoSmithKline Plc. (UK)

MedImmune, LLC. (US)

Novartis AG (Switzerland)

Sanofi Pasteur, SA (France)

Sinovac Biotech Ltd. (China)  
Zydus Cadila (India)

## 10. GLOBAL MARKET PERSPECTIVE

**Table 6.** World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US\$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

**Table 7.** World Historic Review for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US\$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

**Table 8.** World 12-year Analysis for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for the Years 2009, 2015 and 2020 (includes corresponding Graph/Chart)

## III. MARKET

### 1. THE UNITED STATES

#### A. Market Analysis

'Swine Flu' Strain Returns in the 2013-14 Season

Major H1N1 Vaccines Available in the US and Canada

US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus Strain Indicated for 2014-2015 Flu Season

US FDA-Approved Quadrivalent Vaccines Incorporating H1N1 Strain for Influenza Type A and B (2014-15)

Preparations Authorized by Health Canada for Influenza, including H1N1, in Canada (2014-15 season)

Medicare and Medicaid Services for Influenza in the US

**Table 9.** CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016

**Table 10.** CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016

A Historical Perspective on the H1N1 Pandemic in North America

First Case of H1N1 Infection Reported in Mexico

Swine Flu Spreads to the United States

H1N1 Pandemic Linked to Delay in Vaccine Administration

Canadian Government's H1N1 Mass Vaccination Campaign

Product Approvals & Launches

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 11.** The US Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

**Table 12.** The US Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

## 2. EUROPE

A. Market Analysis

H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation

An Insight into European Influenza Vaccination Scenario

Cell-based Vaccine Production Remains Nascent, Egg-based Widely Used

Major Influenza Vaccines Available in European Union Member Countries

Major H1N1 Flu Vaccines Available in Select East European Markets

ECDC Proposes New Influenza Vaccination Strategy

Immunization of High-Risk Demographics

Protecting Children, Adolescents, and Young Adults

Stemming the Spread of Infection in Public Centers

EU Welcomes Quadrivalent LAIVs

Safety Concerns of Influenza Vaccines Abate

Historical Perspective on the H1N1 Pandemic in Europe

Product Approvals & Launches

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 13.** European Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

**Table 14.** European Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

### 3. ASIA-PACIFIC

#### A. Market Analysis

#### 2014-15: DEADLIEST SWINE FLU SEASON IN INDIA SINCE 2009

Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets  
Historical Perspective on The Outbreak of H1N1 Pandemic In 2009 In Select Regions

Japan

South Korea

Taiwan

Malaysia

Philippines

New Zealand

India

China

Hong Kong

Singapore

Australia

Product Approvals & Launches

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 15.** Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)



**Table 16.** Asia-Pacific Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

#### **4. REST OF THE WORLD**

Market Analysis

**Table 17.** Rest of World Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

**Table 18.** Rest of World Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US\$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 33 (including Divisions/Subsidiaries - 36)

The United States (13)

Japan (2)

Europe (8)

France (3)

The United Kingdom (2)

Rest of Europe (3)

Asia-Pacific (Excluding Japan) (13)

## I would like to order

Product name: H1N1 Vaccines: Market Research Report

Product link: <https://marketpublishers.com/r/H18B1E1E4D1EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H18B1E1E4D1EN.html>